Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | DF1001 |
Trade Name | |
Synonyms | DF-1001|DF 1001 |
Drug Descriptions |
DF1001 is a natural killer (NK) cell engager therapy consisting of a trispecific antibody that targets ERBB2 and NK receptors, potentially resulting in increased anti-tumor immune response (PMID: 32054397, PMID: 32934330). |
DrugClasses | HER2 (ERBB2) Antibody 76 |
CAS Registry Number | NA |
NCIT ID | C172279 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
DF1001 | DF1001 | 0 | 1 |
DF1001 + Pembrolizumab | DF1001 Pembrolizumab | 0 | 1 |